Study suggests higher triple-negative breast cancer incidence among black women is not generalizable

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new study found substantial variation in the prevalence of triple-negative breast cancer among black women with breast cancer by birthplace in the U.S.

The prevalence of triple-negative breast cancer was highest among U.S.-born and Western-African–born black women, followed by Caribbean-born, and Eastern-African-born black women.

The study is published in the journal Cancer and its findings suggests the typical notion of higher proportional burden of triple-negative breast cancer among black women is not generalizable to all women of African descent.

Triple-negative breast cancer is approximately twice as common, both in proportion of breast cancers and in incidence rates among black women than white women in the U.S., a factor that is often considered as one contributor to lower breast cancer survival among black patients.

Black populations in the U.S. are diverse, comprising people born in the U.S. as well as immigrants from various countries. Rapidly growing numbers of immigrants from different national and social backgrounds during the most recent three or four decades have reshaped the overall black population in the U.S.

In 2013, about 9% of the black population was documented as being born outside the U.S., with approximately one-half born in the Caribbean, 35% born in Sub-Saharan Africa, and 9% born in Central and South America.

It is also notable the highest levels of within-population genetic diversity have been reported among persons who self-identified as blacks than among those in other racial groups. Still, nativity and geographic origin among black women has seldom been examined, even as nativity-related differences may improve the understanding of the etiologic heterogeneity of breast cancer.

Investigators, led by Hyuna Sung of the American Cancer Society, examined the prevalence of triple-negative and hormone receptor-negative breast cancer among black women in the National Program of Cancer Registries and U.S. Cancer Statistics.

The authors identified 65,211 non-Hispanic black women who were diagnosed with invasive breast cancer from 2010 through 2015 and who were recorded as being born in the U.S., East Africa, West Africa, or the Caribbean.

They found compared with U.S.-born black women, the prevalence rate ratio of triple-negative breast cancer was 13% lower among Caribbean-born women, and 46% lower 0.54 among Eastern-African–born black women.

“It is not clear what risk factors are associated with subtype prevalence by birthplace,” said Sung. “However, the similarity in breast cancer subtype prevalence between U.S.-born and Western-African–born blacks, contrasted against the differences with Eastern-African–born blacks, may in part reflect shared ancestry-related risk factors.”

The authors conclude “presenting breast tumor subtype in black women as a single category is not reflective of the diverse black populations in the nation. Their study “calls for a concerted effort for more complete collection of birthplace information in cancer registries.”

Table of Contents

YOU MAY BE INTERESTED IN

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login